Share

March 26, 2013; 80 (13) Article

Infectious burden and cognitive function

The Northern Manhattan Study

Mira Katan, Yeseon Park Moon, Myunghee Cho Paik, Ralph L. Sacco, Clinton B. Wright, Mitchell S.V. Elkind
First published March 25, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182896e79
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
984

Share

Article Information

vol. 80 no. 13 1209-1215
DOI: 
https://doi.org/10.1212/WNL.0b013e3182896e79
PubMed: 
23530151
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received April 19, 2012
  • Accepted October 30, 2012
  • First Published March 25, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Mira Katan, MD,
    2. Yeseon Park Moon, MS,
    3. Myunghee Cho Paik, PhD,
    4. Ralph L. Sacco, MD, MS,
    5. Clinton B. Wright, MD and
    6. Mitchell S.V. Elkind, MD, MS
  1. Mira Katan, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker Honoraria for presentation of data of the COSMOS study (Clinical Trials. gov number, NCT00390962) from BRAHMS,Berlin 2009.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received within the last 3 years research grants from BRAHMS/ Thermo Fisher Scientific.

    Research Support, Government Entities:

    1. I received within the last 3 years research grants from the Swiss National Science Foundation (PBZHP3-130982)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I am receiving a transatlantic career award from the Fondation Leducq.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Yeseon Park Moon, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Myunghee Cho Paik, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Ralph L. Sacco, MD, MS,
    5. Scientific Advisory Boards:

    1. DSMB for AVERROES Trial through McMaster University Population Health Research Institue (indirect sponsor Pfizer)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Ed Boards: Stroke, Neuroepidemiology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Northern Manhattan Study, PI, 1993-present R37 NS29993 Family Study, PI, 2004-present R01 NS040807

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Evelyn McKnight Brain Institute

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Clinton B. Wright, MD and
    6. Scientific Advisory Boards:

    1. NOCIP DSMB.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Royalties from UpToDate website for two chapters on vascular dementia.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Merck for stroke adjudication related to a clinical trial (ongoing). Nutricia North America for one time advisory committee related to a medical food.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. UpToDate, authorship honoraria.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. American Heart Association SDG 0735387N

    Research Support, Government Entities:

    1. 1) NIH/NINDS K02 NS059729, PI, 2008-2013, 2) NIH/NHLBI R01 HL 108623, PI, 2012-2016, 3) NIH/NINDS R37 NS 29993, CO-I, 2008-2013, 4) NIH, subcontract from Wake Forest, PI, 2009-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mitchell S.V. Elkind, MD, MS
    7. Scientific Advisory Boards:

    1. (1) Jarvik Heart, Clinical Events Committee member, adjudicating events in clinical trial of artificial heart (2008-present)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Resident and Fellow Section editor, published by American Academy of Neurology (2007-present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Boehringer-Ingelheim, Inc., 2009-2010; (2) BMS-Sanofi Pharmaceutical Partnership, 2009-2010; (3) Genentech 2010

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) diaDexus, Inc: funding for biomarker research; (2) BMS-Sanofi Pharmaceutical Partnership: funding for biomarker research

    Research Support, Government Entities:

    1. (1) NIH/NINDS P50 NS049060, Project PI, 2004-2013;(2) NIH/NINDS R37 NS029993, Co-PI, 2008-2013; (3) NIH/NINDS 1R25 NS070697, PI, 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) American Heart Association Founders Affiliate Board of Directors)(2008-present); (2) American Heart Association NY City Board of Directors (2011-present)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) Novartis, Zelnorm and stroke litigation, 2009-2010; (2) GSK, Avandia and stroke liigation, 2009-2011; (3) Organon, NuvaRing and stroke liigation, 2009-present; (4) Boehringer-Ingelheim, Inc., Pradaxa and stroke litigation (2012)

  1. From the Department of Neurology (M.K., Y.P.M., M.S.V.E.) and Department of Epidemiology and Gertrude Sergievsky Center (M.S.V.E.), Columbia University College of Physicians and Surgeons, New York; Department of Biostatistics (M.C.P.), Mailman School of Public Health, Columbia University, New York, NY; and Departments of Neurology, Epidemiology & Public Health, and Neuroscience (R.L.S., C.B.W.), and Department of Genetics (R.L.S.), Miller School of Medicine, University of Miami, Miami, FL.
  1. Correspondence to Dr. Katan: mk3270{at}columbia.edu
View Full Text

Article usage

Article usage: March 2013 to January 2023

AbstractFullPdfSource
Mar 2013551244122Highwire
Apr 201330455894Highwire
May 201313812431Highwire
Jun 201311861417Highwire
Jul 20134651012Highwire
Aug 201318316Highwire
Sep 201323152Highwire
Oct 201333846Highwire
Nov 201319387Highwire
Dec 201315978Highwire
Jan 201417914Highwire
Feb 201424623Highwire
Mar 2014225103Highwire
Apr 201435451Highwire
May 201412851Highwire
Jun 20147671Highwire
Jul 20147852Highwire
Aug 20148080Highwire
Sep 201410792Highwire
Oct 20148691Highwire
Nov 201412803Highwire
Dec 201412410Highwire
Jan 201585105Highwire
Jan 2015086pmc
Feb 20158201Highwire
Feb 20150154pmc
Mar 201515833Highwire
Mar 20150125pmc
Apr 201511724Highwire
Apr 2015062pmc
May 20157622Highwire
May 201502512pmc
Jun 20156600Highwire
Jun 201501312pmc
Jul 20156101Highwire
Jul 20150133pmc
Aug 20156823Highwire
Aug 20150446pmc
Sep 20156130Highwire
Sep 20150195pmc
Oct 20156342Highwire
Oct 2015066pmc
Nov 20153922Highwire
Nov 20150179pmc
Dec 20155413Highwire
Dec 20150157pmc
Jan 20166600Highwire
Jan 20160126pmc
Feb 20166110Highwire
Feb 20160248pmc
Mar 20169800Highwire
Mar 20160186pmc
Apr 20165411Highwire
Apr 20160157pmc
May 20165601Highwire
May 20160155pmc
Jun 20165412Highwire
Jun 2016097pmc
Jul 20164100Highwire
Jul 20160205pmc
Aug 20166212Highwire
Aug 20160229pmc
Sep 20164912Highwire
Sep 20160168pmc
Oct 20168200Highwire
Oct 20160192pmc
Nov 20164901Highwire
Nov 20160155pmc
Dec 20165100Highwire
Dec 20160101pmc
Jan 20175600Highwire
Jan 20170164pmc
Feb 20174401Highwire
Feb 20170226pmc
Mar 20177901Highwire
Mar 20170346pmc
Apr 201713500Highwire
Apr 201731617pmc
May 201712501Highwire
May 201762931pmc
Jun 20179300Highwire
Jun 201762326pmc
Jul 201710201Highwire
Jul 201733134pmc
Aug 20177200Highwire
Aug 201762426pmc
Sep 20178630Highwire
Sep 201754161pmc
Oct 20178111Highwire
Oct 201762830pmc
Nov 20177102Highwire
Nov 201773439pmc
Dec 20172600Highwire
Jan 20185412Highwire
Feb 20184842Highwire
Mar 20187763Highwire
Apr 20184300Highwire
Apr 201822936pmc
May 20184310Highwire
Jun 20185100Highwire
Jun 201883236pmc
Jul 20185100Highwire
Aug 20183611Highwire
Aug 201845056pmc
Sep 20184503Highwire
Oct 20185801Highwire
Nov 20186720Highwire
Dec 20188204Highwire
Jan 20196000Highwire
Feb 20195532Highwire
Mar 20196600Highwire
Apr 20193710Highwire
May 20195100Highwire
Jun 20193032Highwire
Jul 20193811Highwire
Aug 20192621Highwire
Sep 20194022Highwire
Oct 20192621Highwire
Nov 20194511Highwire
Dec 20193101Highwire
Jan 20205603Highwire
Feb 20205911Highwire
Mar 20204132Highwire
Apr 20202454Highwire
May 20204511Highwire
Jun 20203900Highwire
Jul 20202511Highwire
Aug 20202301Highwire
Sep 20204411Highwire
Oct 20204500Highwire
Nov 20204210Highwire
Dec 20205421Highwire
Jan 20213900Highwire
Feb 20212710Highwire
Mar 20218100Highwire
Apr 20218900Highwire
May 20215000Highwire
Jun 20214222Highwire
Jul 20215611Highwire
Aug 20218210Highwire
Sep 20215200Highwire
Oct 20215900Highwire
Nov 20218222Highwire
Dec 20214230Highwire
Jan 20225011Highwire
Feb 20227911Highwire
Mar 202210900Highwire
Apr 20226200Highwire
May 20228012Highwire
Jun 20225437Highwire
Jul 20225001Highwire
Aug 20225722Highwire
Sep 20224910Highwire
Oct 20225000Highwire
Nov 20227220Highwire
Dec 20225300Highwire
Jan 20235411Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me